Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.64 |
| ▸ | HTR2A | P28223 | 1/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.55 |
| ▸ | HTR7 | P34969 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | PRKCB | P05771 | 2/20 | 0.52 |
| ▸ | PRKCA | P17252 | 2/20 | 0.52 |
| ▸ | PRKCH | P24723 | 2/20 | 0.52 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.52 |
| ▸ | PRKCQ | Q04759 | 2/20 | 0.52 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.51 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | PAK4 | O96013 | 1/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.51 |
| ▸ | MET | P08581 | 1/20 | 0.51 |
| ▸ | PIM1 | P11309 | 1/20 | 0.51 |
| ▸ | PRKACA | P17612 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5787241 | 0.99 | ALDH1A1 (0.63) | ALDH1A1HPGDHTR2AADORA2AHTR7 | |
| SCHEMBL5787992 | 0.88 | HTR2A (0.53) | ALDH1A1HPGDHTR2AHTR7PRKCB | |
| SCHEMBL5787058 | 0.84 | ALDH1A1 (0.69) | ALDH1A1HPGDHTR2AADORA2AHTR7 | |
| Hydrochloric Acid SCHEMBL5790067 | 0.82 | ALDH1A1 (0.67) | ALDH1A1HPGDHTR2AADORA2AHTR7 | |
| SCHEMBL5790102 | 0.81 | ALDH1A1 (0.69) | ALDH1A1HPGDHTR2AADORA2ATSHR | |
| SCHEMBL5788388 | 0.81 | ALDH1A1 (0.69) | ALDH1A1HPGDHTR2ATSHRPRKCB | |
| Hydrochloric Acid SCHEMBL5789347 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HPGDHTR2ATSHRPRKCB | |
| Hydrochloric Acid SCHEMBL5789717 | 0.80 | ALDH1A1 (0.67) | ALDH1A1HPGDHTR2AADORA2ATSHR | |
| SCHEMBL15824624 | 0.80 | ALDH1A1 (0.63) | ALDH1A1HPGDHTR2AHTR7TSHR | |
| SCHEMBL9216241 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDHTR2ATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | claimed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | claimed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | claimed |
| US-9868707-B2 | Small molecule agonists of neurotensin receptor 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-01-16 | — | — | US | disclosed |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | DUKE UNIVERSITY (US) | 2015-11-19 | — | — | US | disclosed |
| EP-2938608-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | Sanford-Burnham Medical Research Institute (US) | 2015-11-04 | — | — | EP | disclosed |
| WO-2014100501-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2014-06-26 | — | — | WO | disclosed |
| EP-1685115-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | Warner-Lambert Company LLC (US) | 2006-08-02 | — | — | EP | disclosed |
| WO-2005042501-A1 | NOVEL NOREPINEPHRINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2005-05-12 | — | — | WO | disclosed |
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | WARNER-LAMBERT COMPANY LLC | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096327-A1 | Novel norepinephrine reuptake inhibitors for the treatment of central nervous system disorders | SLC6A2, SLC18A2, SLC6A3 | ALDH1A1 730/4885HPGD 2714/4885HTR2A 52/4885 |
| US-20150329497-A1 | SMALL MOLECULE AGONISTS OF NEUROTENSIN RECEPTOR 1 | NTSR1, NTSR2, VIPR1 | ALDH1A1 3294/4885HPGD 2659/4885HTR2A 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.